Delving into the Latest Updates on Brise Pharmaceuticals Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Cardiovascular Diseases

Small molecule drug

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	9

Top 5 Drug Type	Count

Unknown	5
Small molecule drug	4
Monoclonal antibody	1

Top 5 Target	Count

CGRP(Calcitonin gene-related peptide)	1
TRPM3(transient receptor potential cation channel subfamily M member 3)	1
TrkA(Nerve growth factor receptor Trk-A)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Oct 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

6

2

Preclinical

Phase 1

1

Phase 3

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BR005-036C ( CGRP )	Acute migraine More	Phase 1
Recombinant humanized anti-TrkA monoclonal antibody(Brise Pharmaceutical) ( TrkA )	Low Back Pain More	Phase 1
BR008	Neuralgia More	Preclinical
BR009	Migraine Disorders More	Preclinical
WO2025247396 Patent Mining	Arrhythmias, Cardiac More	Discovery